Showing results (461-470 of 509) with videos related to

Sort By:
Pageof 51
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2015
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responsesAriane Hammitzsch, Cynthia Tallant, Oleg Fedorov, et al.
Blood|September 20, 2017
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapyKevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2007
Aminopyrrolidineamide inhibitors of site-1 proteaseBruce A Hay, Barbara Abrams, Allice Y Zumbrunn, et al.
Blood Advances|November 20, 2019
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapyJoshua A Hill, Elizabeth M Krantz, Kevin A Hay, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 26, 2008
Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animalsJulie L Hawkins, Michael D Robbins, Laurie C Warren, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitorsStephen M Courtney, Philip A Hay, Richard T Buck, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Design and optimisation of potent gp120-CD4 inhibitorsThien-Duc Tran, Fiona M Adam, Frederick Calo, et al.
Cytotherapy|May 31, 2024
Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell productsBo Angela Wan, Lorenzo Lindo, Yasser Abou Mourad, et al.
Blood Advances|October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapyMazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
European Journal of Medicinal Chemistry|November 19, 2024
Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosisHenry Danahay, Martin Gosling, Roy Fox, et al.
Pageof 51